Endpoints News
Arikayce could become Insmed’s second blockbuster following late-stage win in lung infection
Insmed’s Phase 3 trial win for Arikayce in a particular kind of lung infection sets up the drug to expand into the front-line setting — possibly giving the biotech a second projected blockbuster.
The company said …